Table 1

Patient characteristics at baseline

Exposed (n=23)Unexposed (n=164)p Value
Mean±SD age (years)65.6 ± 8.158.3 ± 12.40.007
Women, n (%)12 (52.2)130 (79.8)0.004
Mean±SD disease duration (years)13.6 ± 7.812.2 ± 6.90.355
Mean±SD DAS285.3 ±1.15.3 ± 1.20.999
ESR, median (P25–P75)26.0 (20.0–46.0)32.5 (18.0–47.0)0.845
SJC, median (P25–P75)9.0 (4.0–13.0)9.0 (4.0–12.0)0.864
TJC, median (P25–P75)8.0 (4.0–13.0)6.0 (3.0–11.0)0.387
VAS GH, median (P25–P75)67.0 (50–80)63.0 (40.0–75.0)0.245
Glucocorticoids (oral), n (%)13 (56.5)93 (56.7)1.000
Dose (mg), median (P25–P75)10.0 (5.0–15.0)10.0 (5.0–10.0)0.062
Glucocorticoids (im/ia), n (%)4 (17.4)27 (16.5)1.000
Dose (mg), median (P25–P75)120.0 (105.0–120.0)120.0 (80.0–120.0)0.368
Previous DMARDS*, median (P25–P75)6.0 (4.0–9.0)5.0 (4.0–7.0)0.129
Previous anti-TNF*, median (P25–P75)3.0 (2.0–4.0)3.0 (2.0–4.0)0.715
Co-therapy with methotrexate, n (%)15 (65.2)98 (79.3)0.616
Rheumatoid factor +, n (%)21 (79.3)130 (91.3)0.170
Mean±SD duration statin use (years)2.8 ± 3.0
Patients who completed a course of RTX§, n (%)23 (100%)164 (100%)0.342
  • * Medication prescribed prior to the start of treatment with RTX.

  • Concomitant prescription of methotrexate at start of RTX treatment.

  • Duration of statin use at baseline.

  • § A complete course of RTX consists of two infusions 2 weeks apart.

  • DAS28, Disease Activity Score using 28 joint counts; ESR, erythrocyte sedimentation rate; ia, intra-articular injection; im, intramuscular injection; RTX, rituximab; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; VAS GH, visual analogue scale general health.